Optimizing Myelofibrosis Care: Nursing Perspectives on JAK Inhibitors

Join us for Optimizing Myelofibrosis Care: Nursing Perspectives on JAK Inhibitors on Thursday, September 11, 2025, at the Ohio State Eye and Ear Institute

Sandra Kurtin, PhD, ANP-BC, AOCN, FAPO - Assistant Professor of Clinical Medicine Professor at The University of Arizona nad Diretor of Advanced Practice at The University of Arizonza Cancer Center in Tucson, AZ.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

• Review the clinical features of myelofibrosis, including risk stratification, indicators of disease prognosis, and symptom burden

• Identify the expected outcomes and therapeutic goals associated with JAK inhibitor treatment in myelofibrosis care

• Develop individualized strategies to reduce treatment toxicity and enhance treatment adherence for patients with myelofibrosis

• Educate patients about the purpose of JAK inhibitors, potential side effects, adherence to Medic*tion schedules, and the importance of regular monitoring and follow-up appointments

Don't miss out on this opportunity to network with an expert in the field and get up-to-date information on the latest research. See you there!

Nurses (ANCC)

This activity is designated for 1.0 contact hour.

Pharmacotherapy—ANCC definition of pharmacotherapeutic content is that it may include but is not limited to drug-specific information, safe prescribing practices, safe Medic*tion administration, prescribing methodologies, new regulations, or similar content.

Note to Nurse Practitioners—The content of this CNE activity pertains to Pharmacology.

Oncology Nursing Certification (ONCC) [ILNA]

This activity is designated for 1.0 contact hour. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Host or Publisher The Columbus Chapter of the Oncology Nursing Society (CCONS)